AnaptysBio, Inc. (0HFQ.L)

26,22 +0,15 (+0,58%) Alla chiusura: 06:53PM BST

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
United States
858 362 6295
https://www.anaptysbio.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 117

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel R. Faga	President, CEO & Director	2,52M	N/D	1980
Mr. Eric J. Loumeau	Chief Legal Officer	722k	N/D	1963
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.	Chief Medical Officer	738,87k	N/D	1975
Mr. Dennis M. Mulroy	Chief Financial Officer	448,81k	N/D	1955
Ms. Beth Mueller	Senior Vice President of Human Resources	N/D	N/D	N/D
Dr. Martin Dahl Ph.D.	Senior Vice President of Research	N/D	N/D	N/D
Mr. Benjamin Stone	Chief Business Officer	N/D	N/D	N/D
Mr. Douglas A. Rich M.B.A.	Senior Vice President of CMC	N/D	N/D	1969
Ms. Monique Da Silva	Senior Vice President of Corporate Affairs	N/D	N/D	N/D
Ms. Priya Raina	Senior Vice President of Clinical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di AnaptysBio, Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.